India Pharmaceuticals Manufacturing Market Strategic Research Report 2026-2031

Publication ID:

NAV0826018

Publication Date:

August 26, 2026

Pages:

251

Countries:

India [1]

India's pharmaceutical manufacturing output is estimated at USD 30.5 billion in 2025 (base year), forecast to reach USD 55.5 billion by 2031, at a CAGR of approximately 10.5% across the 2025–2031 forecast period. Real historical data spans 2022–2024 (USD 22.5 billion in 2022). India supplies approximately 40% of global generic medicine volume and 57% of APIs imported by the United States, with 1,200+ USFDA-approved manufacturing facilities - the largest concentration outside the United States.

This report independently verifies all 18 profiled companies' financial figures directly against their own official investor relations disclosures and annual reports, following a rigorous data refresh completed in August 2026 that identified and corrected several real discrepancies between commonly-cited estimates and companies' actual reported results - including India's real, PharmExcil-confirmed FY2026 pharmaceutical export figure of USD 31.11 billion, and a corrected breakdown of the Production-Linked Incentive (PLI) scheme's two sub-programmes (Pharma/Drugs PLI and Bulk Drugs/API PLI), whose real disbursement data revealed a meaningfully slower capacity ramp for API manufacturing specifically than for finished formulations.

This report provides full segmentation by manufacturing type and export application/destination, together with regional and state-level manufacturing geography across West India, North India, South India, East India, and Central India, plus company profiles, Porter's Five Forces, PESTLE, SWOT analysis, and future trends through 2031, including the CDMO/China+1 structural reallocation and GLP-1 peptide manufacturing buildout.

Scope of India Pharmaceuticals Manufacturing Market Strategic Research Report

This report provides forecast data by value (USD Billion) for India's pharmaceutical manufacturing output, with 2025 as the base year, real historical data from 2022, and forecasting to 2031.
This report provides segment by type (Finished Dosage Formulations (FDF), Active Pharmaceutical Ingredients (API), Biologics & Biosimilars, CDMO / CRAMS Services, Medical Nutrition & Other) forecast data by value.
This report provides application/export-destination segments (Domestic Application (India consumption), Export Application - United States, Export Application - Europe, Export Application - Africa, Export Application - Asia-Pacific, Export Application - Latin America, Export Application - MEA, Export Application - Rest of World) forecast data by value.
This report provides region-wise (West India, North India, South India, East India, Central India) manufacturing geography forecast data by value.
This report also provides full state-wise manufacturing cluster forecast data across all five regions.
This report identifies key growth drivers and inhibitors affecting India's pharmaceutical manufacturing sector, including the PLI scheme, China+1 reshoring, and CDMO/CRAMS expansion.
This report provides company profiles including Company Overview, Key Products & Segments, Financial Performance, Business Strategy, and SWOT Analysis for 251-page-detailed, officially-verified companies.
This report provides Porter's Five Forces, PESTLE, and SWOT analysis for India's pharmaceutical manufacturing industry.
This report identifies key future trends, including biosimilar manufacturing leadership, GLP-1 peptide manufacturing, API self-reliance, and digital manufacturing transformation.

Segment by Type in India Pharmaceuticals Manufacturing Market Strategic Research Report

Finished Dosage Formulations (FDF)
Active Pharmaceutical Ingredients (API)
Biologics & Biosimilars
CDMO / CRAMS Services
Medical Nutrition & Other

Segment by Application in India Pharmaceuticals Manufacturing Market Strategic Research Report

Domestic Application (India consumption)
Export Application - United States
Export Application - Europe
Export Application - Africa
Export Application - Asia-Pacific
Export Application - Latin America
Export Application - MEA
Export Application - Rest of World

Segment by Region in India Pharmaceuticals Manufacturing Market Strategic Research Report

West India
- Maharashtra
- Gujarat
- Goa
North India
- Himachal Pradesh
- Uttarakhand
- Haryana
- Punjab
South India
- Telangana
- Andhra Pradesh
- Karnataka
- Tamil Nadu
East India
- West Bengal
- Odisha
- Bihar
Central India
- Madhya Pradesh
- Chhattisgarh

Who can use the India Pharmaceuticals Manufacturing Market Strategic Research Report?

This research report is ideal for people who wish to gain a thorough understanding of India's pharmaceutical manufacturing industry. Some of the intended users for this report are:

C-level executives and Company Directors in pharmaceutical manufacturing and CDMO companies
Industry consultants and Management consultants
Supply chain and manufacturing strategy professionals
Investment managers, Financial professionals, and Venture Capitalists
Bank Managers, M&A Managers, and Auditors
Trade policy analysts and Government/regulatory affairs professionals
Portfolio Managers and Equity Research Analysts covering Indian pharmaceutical manufacturers
Anyone operating in the global pharmaceutical manufacturing and CDMO value chain

Executive Summary
1. 1.1 India Pharmaceuticals Manufacturing Market Strategic Research Report 2026–2031
2. 1.2 Market Positioning & Scale
3. 1.3 Market Size & Forecast Trajectory
4. 1.4 Key Strategic Findings
5. 1.4.1 Generic Volume Leadership and Export Dominance
6. 1.4.2 PLI Scheme — Policy-Led Manufacturing Deepening
7. 1.4.3 GLP-1 Biosimilar First-Mover Positioning
8. 1.4.4 CDMO and China+1 Structural Tailwind
9. 1.4.5 Biosimilar Export Commercialisation
10. 1.4.6 Hyderabad — The API Capital of India
11. 1.5 FY2025–26 Data Refresh: Methodology and Confidence
12. 1.6 Segment Architecture and Report Structure
13. 1.7 Strategic Outlook
Industry Overview & Forecast
1. 2.1 India's Pharmaceutical Manufacturing Market — Scale, Structure, and Trajectory
2. 2.2 Segment Architecture — How the USD 55.5 Billion Breaks Down
3. 2.3 Export Architecture — USD 14.5 Billion to USD 23.6 Billion
4. 2.4 Regional Manufacturing Geography
5. 2.5 The Company Revenue Foundation
6. 2.6 Gross Manufacturing Output — Contextualising the USD 62 Billion Gross Production Figure
7. 2.7 Growth Rate Architecture — CAGR Verification and Segment Differentials
3. Market Segmentation by Type
1. 3.1 Overview and Structural Composition
2. 3.2 Finished Dosage Formulations — The Dominant Segment
3. 3.3 Active Pharmaceutical Ingredients — China+1 Reshoring Drives Structural Capacity Growth
4. 3.4 Biologics & Biosimilars — The High-Growth Frontier
5. 3.5 CDMO/CRAMS Services — China+1 Demand Drives Structural Capacity Investment
6. 3.6 Medical Nutrition & Other — Stable Contributor with Premiumisation Upside
7. 3.7 Cross-Segment Portfolio Dynamics and Convergence Trends
Market Segmentation by Application
1. 4.1 Overview and Structural Framework
2. 4.2 Domestic Application — India's Own Formulation Consumption
3. 4.3 Export Application — United States
4. 4.4 Export Application — Europe
5. 4.5 Export Application — Africa
6. 4.6 Export Application — Asia-Pacific
7. 4.7 Export Application — Latin America
8. 4.8 Export Application — Middle East and Africa (MEA)
9. 4.9 Export Application — Rest of World
10. 4.10 Other Segments — Biologics, CDMO, API, and Medical Nutrition
11. 4.11 Application Segment Synthesis — Competitive Positioning and Forecast Summary
Regional Market Forecast
1. 5.1 West India
2. 5.1.1 Regional Overview
3. 5.1.2 Key Growth Drivers
4. 5.1.3 Regulatory & Infrastructure Landscape
5. 5.1.4 Country-Level Analysis
6. 5.1.5 Market Forecast 2025–2031
7. India Pharmaceuticals Manufacturing Market Strategic Research Report 2026-2031
8. 5.2 South India
9. 5.2.1 Regional Overview
10. 5.2.2 Key Growth Drivers
11. 5.2.3 Regulatory & Infrastructure Landscape
12. 5.2.4 Country-Level Analysis
13. 5.2.5 Market Forecast 2025–2031
14. 5.3 North India
15. 5.3.1 Regional Overview
16. 5.3.2 Key Growth Drivers
17. 5.3.3 Regulatory & Infrastructure Landscape
18. 5.3.4 Country-Level Analysis
19. 5.3.5 Market Forecast 2025–2031
20. 5.4 East India
21. 5.4.1 Regional Overview
22. 5.4.2 Key Growth Drivers
23. 5.4.3 Regulatory & Infrastructure Landscape
24. 5.4.4 Country-Level Analysis
25. 5.4.5 Market Forecast 2025–2031
26. 5.5 Central India
27. 5.5.1 Regional Overview
28. 5.5.2 Key Growth Drivers
29. 5.5.3 Regulatory & Infrastructure Landscape
30. 5.5.4 Country-Level Analysis
31. 5.5.5 Market Forecast 2025–2031
Country-Level Market Forecast
1. 6.1 West India
2. 6.1.1 Gujarat (Ankleshwar, Vapi, Vadodara)
3. 6.1.2 Maharashtra (Aurangabad, Mumbai)
4. 6.1.3 Goa
5. 6.2 South India
6. 6.2.1 Telangana (Hyderabad Genome Valley)
7. 6.2.2 Andhra Pradesh (Visakhapatnam)
8. 6.2.3 Karnataka (Bangalore)
9. 6.2.4 Tamil Nadu (Chennai)
10. 6.3 North India
11. 6.3.1 Himachal Pradesh (Baddi/Solan)
12. 6.3.2 Uttarakhand (Haridwar/Pantnagar)
13. 6.3.3 Haryana
14. 6.3.4 Punjab
15. 6.4 East India
16. 6.4.1 West Bengal
17. 6.4.2 Odisha
18. 6.4.3 Bihar
19. 6.5 Central India
20. 6.5.1 Madhya Pradesh
21. 6.5.2 Chhattisgarh
Growth Drivers & Inhibitors
1. 7.1 Section Overview
2. 7.2 Growth Drivers
3. 7.2.1 Generic Export Demand & Global Healthcare Access Imperatives
4. 7.2.2 Production-Linked Incentive (PLI) Scheme — Policy-Driven Capacity Investment
5. 7.2.3 API Self-Reliance & China+1 Strategic Diversification
6. 7.2.4 Biologics & Biosimilar Manufacturing — High-Value Segment Acceleration
7. 7.2.5 CDMO/CRAMS Market Expansion — Structural Contract Manufacturing Growth
8. 7.2.6 Demographic & Domestic Consumption Growth
9. India Pharmaceuticals Manufacturing Market Strategic Research Report 2026-2031
10. 7.3 Growth Inhibitors
11. 7.3.1 Regulatory Compliance Costs & USFDA Warning Letters
12. 7.3.2 China API Import Dependency — Supply Chain Vulnerability
13. 7.3.3 Skilled Workforce Constraints & Talent Attrition
14. 7.3.4 Pricing Pressure & DPCO Coverage Expansion
15. 7.3.5 Infrastructure Gaps & Environmental Compliance Costs
16. 7.3.6 Geopolitical Trade Policy Risk
17. 7.4 Net Assessment: Driver-Inhibitor Balance
Key Company Profiles
1. 8.1 Sun Pharmaceutical
2. 8.1.1 Company Overview
3. 8.1.2 Key Products & Segments
4. 8.1.3 Financial Performance (2023–2025)
5. 8.1.4 Business Strategy
6. 8.1.5 SWOT Analysis
7. 8.1.6 Strategic Implications (2025–2031)
8. 8.2 Aurobindo Pharma
9. 8.2.1 Company Overview
10. 8.2.2 Key Products & Segments
11. 8.2.3 Financial Performance (2023–2025)
12. 8.2.4 Business Strategy
13. 8.2.5 SWOT Analysis
14. 8.2.6 Strategic Implications (2025–2031)
15. 8.3 Dr. Reddy's Labs
16. 8.3.1 Company Overview
17. 8.3.2 Key Products & Segments
18. 8.3.3 Financial Performance (2023–2025)
19. 8.3.4 Business Strategy
20. 8.3.5 SWOT Analysis
21. 8.3.6 Strategic Implications (2025–2031)
22. 8.4 Cipla
23. 8.4.1 Company Overview
24. 8.4.2 Key Products & Segments
25. 8.4.3 Financial Performance (2023–2025)
26. 8.4.4 Business Strategy
27. 8.4.5 SWOT Analysis
28. 8.4.6 Strategic Implications (2025–2031)
29. 8.5 Lupin
30. 8.5.1 Company Overview
31. 8.5.2 Key Products & Segments
32. 8.5.3 Financial Performance (2023–2025)
33. 8.5.4 Business Strategy
34. 8.5.5 SWOT Analysis
35. 8.5.6 Strategic Implications (2025–2031)
36. 8.6 Zydus Lifesciences
37. 8.6.1 Company Overview
38. 8.6.2 Key Products & Segments
39. 8.6.3 Financial Performance (2023–2025)
40. 8.6.4 Business Strategy
41. 8.6.5 SWOT Analysis
42. 8.6.6 Strategic Implications (2025–2031)
43. 8.7 Biocon Ltd
44. 8.7.1 Company Overview
45. 8.7.2 Key Products & Segments
46. 8.7.3 Financial Performance (2023–2025)
47. India Pharmaceuticals Manufacturing Market Strategic Research Report 2026-2031
48. 8.7.4 Business Strategy
49. 8.7.5 SWOT Analysis
50. 8.7.6 Strategic Implications (2025–2031)
51. 8.8 Alkem Laboratories
52. 8.8.1 Company Overview
53. 8.8.2 Key Products & Segments
54. 8.8.3 Financial Performance (2023–2025)
55. 8.8.4 Business Strategy
56. 8.8.5 SWOT Analysis
57. 8.8.6 Strategic Implications (2025–2031)
58. 8.9 Torrent Pharmaceuticals
59. 8.9.1 Company Overview
60. 8.9.2 Key Products & Segments
61. 8.9.3 Financial Performance (2023–2025)
62. 8.9.4 Business Strategy
63. 8.9.5 SWOT Analysis
64. 8.9.6 Strategic Implications (2025–2031)
65. 8.10 Divi's Laboratories
66. 8.10.1 Company Overview
67. 8.10.2 Key Products & Segments
68. 8.10.3 Financial Performance (2023–2025)
69. 8.10.4 Business Strategy
70. 8.10.5 SWOT Analysis
71. 8.10.6 Strategic Implications (2025–2031)
72. 8.11 Piramal Pharma
73. 8.11.1 Company Overview
74. 8.11.2 Key Products & Segments
75. 8.11.3 Financial Performance (2023–2025)
76. 8.11.4 Business Strategy
77. 8.11.5 SWOT Analysis
78. 8.11.6 Strategic Implications (2025–2031)
79. 8.12 Mankind Pharma
80. 8.12.1 Company Overview
81. 8.12.2 Key Products & Segments
82. 8.12.3 Financial Performance (2023–2025)
83. 8.12.4 Business Strategy
84. 8.12.5 SWOT Analysis
85. 8.12.6 Strategic Implications (2025–2031)
86. 8.13 Gland Pharma
87. 8.13.1 Company Overview
88. 8.13.2 Key Products & Segments
89. 8.13.3 Financial Performance (2023–2025)
90. 8.13.4 Business Strategy
91. 8.13.5 SWOT Analysis
92. 8.13.6 Strategic Implications (2025–2031)
93. 8.14 Ipca Laboratories
94. 8.14.1 Company Overview
95. 8.14.2 Key Products & Segments
96. 8.14.3 Financial Performance (2023–2025)
97. 8.14.4 Business Strategy
98. 8.14.5 SWOT Analysis
99. 8.14.6 Strategic Implications (2025–2031)
100. 8.15 Granules India
101. 8.15.1 Company Overview
102. 8.15.2 Key Products & Segments
103. India Pharmaceuticals Manufacturing Market Strategic Research Report 2026-2031
104. 8.15.3 Financial Performance (2023–2025)
105. 8.15.4 Business Strategy
106. 8.15.5 SWOT Analysis
107. 8.15.6 Strategic Implications (2025–2031)
108. 8.16 Jubilant Pharmova
109. 8.16.1 Company Overview
110. 8.16.2 Key Products & Segments
111. 8.16.3 Financial Performance (2023–2025)
112. 8.16.4 Business Strategy
113. 8.16.5 SWOT Analysis
114. 8.16.6 Strategic Implications (2025–2031)
115. 8.17 Ajanta Pharma
116. 8.17.1 Company Overview
117. 8.17.2 Key Products & Segments
118. 8.17.3 Financial Performance (2023–2025)
119. 8.17.4 Business Strategy
120. 8.17.5 SWOT Analysis
121. 8.17.6 Strategic Implications (2025–2031)
122. 8.18 Natco Pharma
123. 8.18.1 Company Overview
124. 8.18.2 Key Products & Segments
125. 8.18.3 Financial Performance (2023–2025)
126. 8.18.4 Business Strategy
127. 8.18.5 SWOT Analysis
128. 8.18.6 Strategic Implications (2025–2031)
9. Competitive Landscape
1. 9.1 Competitive Landscape Overview
2. 9.2 Competitive Intensity Assessment
3. 9.2.1 Player Tier Structure and Revenue Ranges
4. 9.2.2 Capacity Versus Demand Dynamics
5. 9.2.3 Pricing Environment: Premium, Value, and Commoditised Segments
6. 9.2.4 Barriers to Entry and Exit
7. 9.3 Key Player Strategies & Positioning
8. 9.3.1 Strategic Group Map: Five Competitive Archetypes
9. 9.3.2 Key Player Comparative Metrics (FY2024 Baseline)
10. 9.3.3 M&A and Partnership Activity (2022–Present)
11. 9.3.4 Geographic Strongholds and R&D Investment Trends
12. 9.4 Competitive Dynamics & Strategic Outlook
13. 9.4.1 Emerging Competitive Threats
14. 9.4.2 Consolidation vs. Fragmentation Outlook
15. 9.4.3 Competitive Response Matrix
16. 9.4.4 Strategic Recommendations for 2025–2031
Porter's Five Forces Analysis
1. 10.1 Threat of New Entrants
2. 10.2 Bargaining Power of Buyers
3. 10.3 Bargaining Power of Suppliers
4. 10.4 Threat of Substitutes
5. 10.5 Competitive Rivalry
PESTLE Analysis
1. 11.1 Political
2. 11.2 Economic
3. 11.3 Social
4. 11.4 Technological
5. 11.5 Legal and Regulatory
6. India Pharmaceuticals Manufacturing Market Strategic Research Report 2026-2031
7. 11.6 Environmental
8. 11.7 PESTLE Summary Assessment
SWOT Analysis
1. 12.1 Overview
2. 12.2 Strengths
3. 12.2.1 Scale, Regulatory Approvals, and Global Supply Dominance
4. 12.2.2 Cost-Competitiveness and Labour Productivity
5. 12.2.3 Biologics and Biosimilar Leadership
6. 12.2.4 CDMO Capabilities and China+1 Capture
7. 12.3 Weaknesses
8. 12.3.1 API Import Dependency on China
9. 12.3.2 Quality and Compliance Vulnerabilities
10. 12.3.3 Underdeveloped Domestic Innovation Ecosystem
11. 12.3.4 Infrastructure and Logistics Constraints
12. 12.4 Opportunities
13. 12.4.1 GLP-1 API and Biosimilar First-Mover Advantage
14. 12.4.2 PLI Scheme — Catalytic Investment Multiplier
15. 12.4.3 China+1 CDMO Demand Acceleration
16. 12.4.4 Regulated Market Generic Volume Wave (Patent Cliff 2025–2030)
17. 12.4.5 Emerging Market Demand and South-South Trade Flows
18. 12.5 Threats
19. 12.5.1 US Generic Pricing Pressure and Market Consolidation
20. 12.5.2 Geopolitical Risk and US Trade Policy Uncertainty
21. 12.5.3 Intensifying Chinese Pharmaceutical Manufacturing Competition
22. 12.5.4 Regulatory Risk and Compliance Cost Escalation
23. 12.5.5 Currency and Input Cost Volatility
24. 12.6 SWOT Matrix Summary
Future Trends & Outlook
1. 13.1 Strategic Context
2. 13.2 Biosimilar Manufacturing Leadership and the Export Wave
3. 13.3 GLP-1 Peptide Manufacturing
4. 13.4 API Self-Reliance
5. 13.5 CDMO Sector: Capturing the China+1 Structural Reallocation
6. 13.6 Digital Manufacturing Transformation and Industry 4.0 Adoption
7. 13.7 Regulatory Market Access Expansion
8. 13.8 Consolidated Outlook

List of Exhibits

Exhibit 1: 3.1: Forecast of Finished Dosage Formulations (FDF) (in USD Bn)
Exhibit 2: 3.2: Forecast of Domestic Market (India) (in USD Bn)
Exhibit 3: 3.3: Forecast of Export Market (USA) (in USD Bn)
Exhibit 4: 3.4: Forecast of Export Market (Europe) (in USD Bn)
Exhibit 5: 3.5: Forecast of Export Market (Africa/ROW) (in USD Bn)
Exhibit 6: 3.6: Forecast of Active Pharmaceutical Ingredients (API) (in USD Bn)
Exhibit 7: 3.7: Forecast of Regulated Markets API (US/EU GMP) (in USD Bn)
Exhibit 8: 3.8: Forecast of Semi-Regulated Markets API (in USD Bn)
Exhibit 9: 3.9: Forecast of Domestic Market API (in USD Bn)
Exhibit 10: 3.10: Forecast of Biologics & Biosimilars (in USD Bn)
Exhibit 11: 3.11: Forecast of Biocon Biologics (ex-partner) (in USD Bn)
Exhibit 12: 3.12: Forecast of Dr Reddy's Biologics (in USD Bn)
Exhibit 13: 3.13: Forecast of Cipla Biologics & Others (in USD Bn)
Exhibit 14: 3.14: Forecast of CDMO / CRAMS Services (in USD Bn)
Exhibit 15: 3.15: Forecast of Divi's Laboratories (in USD Bn)
Exhibit 16: 3.16: Forecast of Piramal Pharma CDMO (in USD Bn)
Exhibit 17: 3.17: Forecast of Gland Pharma Injectables (in USD Bn)
Exhibit 18: 3.18: Forecast of Medical Nutrition & Other (in USD Bn)
Exhibit 19: 4.19: Forecast of Domestic Application (India consumption) (in USD Bn)
Exhibit 20: 4.20: Forecast of Segment Application (in USD Bn)
Exhibit 21: 4.21: Forecast of Export Application — United States (in USD Bn)
Exhibit 22: 4.22: Forecast of Export Application — MEA (in USD Bn)
Exhibit 23: 4.23: Forecast of Export Application — Europe (in USD Bn)
Exhibit 24: 4.24: Forecast of Export Application — Africa (in USD Bn)
Exhibit 25: 4.25: Forecast of Export Application — Asia-Pacific (in USD Bn)
Exhibit 26: 4.26: Forecast of Export Application — Latin America (in USD Bn)
Exhibit 27: 4.27: Forecast of Export Application — Rest of World (in USD Bn)
Exhibit 28: 6.28: Forecast of India (in USD Bn)
Exhibit 29: 6.29: Forecast of West India (in USD Bn)
Exhibit 30: 6.30: Forecast of West India (in USD Bn)
Exhibit 31: 6.31: Forecast of South India (in USD Bn)
Exhibit 32: 6.32: Forecast of South India (in USD Bn)
Exhibit 33: 6.33: Forecast of North India (in USD Bn)
Exhibit 34: 6.34: Forecast of North India (in USD Bn)
Exhibit 35: 6.35: Forecast of East India (in USD Bn)
Exhibit 36: 6.36: Forecast of East India (in USD Bn)
Exhibit 37: 6.37: Forecast of Central India (in USD Bn)
Exhibit 38: 6.38: Forecast of Central India (in USD Bn)
Exhibit 39: 6.39: Forecast of Gujarat (Ankleshwar, Vapi, Vadodara) (in USD Bn)
Exhibit 40: 6.40: Forecast of Maharashtra (Aurangabad, Mumbai) (in USD Bn)
Exhibit 41: 6.41: Forecast of Goa (in USD Bn)
Exhibit 42: 6.42: Forecast of Telangana (Hyderabad Genome Valley) (in USD Bn)
Exhibit 43: 6.43: Forecast of Andhra Pradesh (Visakhapatnam) (in USD Bn)
Exhibit 44: 6.44: Forecast of Karnataka (Bangalore) (in USD Bn)
Exhibit 45: 6.45: Forecast of Tamil Nadu (Chennai) (in USD Bn)
Exhibit 46: 6.46: Forecast of Himachal Pradesh (Baddi/Solan) (in USD Bn)
Exhibit 47: 6.47: Forecast of Uttarakhand (Haridwar/Pantnagar) (in USD Bn)
Exhibit 48: 6.48: Forecast of Haryana (in USD Bn)
Exhibit 49: 6.49: Forecast of Punjab (in USD Bn)
Exhibit 50: 6.50: Forecast of West Bengal (in USD Bn)
Exhibit 51: 6.51: Forecast of Odisha (in USD Bn)
Exhibit 52: 6.52: Forecast of Bihar (in USD Bn)
Exhibit 53: 6.53: Forecast of Madhya Pradesh (in USD Bn)
Exhibit 54: 6.54: Forecast of Chhattisgarh (in USD Bn)
Exhibit 55: 6.55: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)

Sun Pharmaceutical, Aurobindo Pharma, Dr. Reddy's Labs, Cipla, Lupin, Zydus Lifesciences, Biocon, Alkem Laboratories, Torrent Pharmaceuticals, Divi's Laboratories, Piramal Pharma, Mankind Pharma, Gland Pharma, Ipca Laboratories, Granules India, Jubilant Pharmova, Ajanta Pharma, Natco Pharma

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.